Strategy for the control of drug-induced liver injury due to investigational treatments/drugs for COVID-19

Table 1 Anti-coronavirus disease 2019 drugs and drugs for drug-induced liver injury

Name	Type	Mechanisms as anti-COVID-19 drugs and/or drugs for drug-induced liver injury	Mechanisms of hepatotoxicity	Ref.
Anti-COVID-19 drugs
Dexamethasone	Anti-inflammatory drug	Amelioration of inflammatory organ injury in viral pneumonia. Alleviation of tissue damage caused by inflammatory responses of the immune system within the liver.	Drug-drug interactions due to cytochrome P450 induction. Elevation of liver enzyme levels, increase in hepatic lipid peroxidation, and decrease in antioxidant activities.	[2,6,7]
Remdesivir	Antiviral drug	Inhibition of RNA polymerase, as a nucleotide analog.	Hepatocellular toxicity.	[10]
Drugs for drug-induced liver injury
Glycyrrhizic acid	Hepatoprotector	Regulation of the expression of hepatobiliary membrane transporters.		[12]
Ursodeoxycholic acid	Hepatoprotector	Anti-inflammatory, antioxidant, immunomodulatory and antiapoptotic profiles. Inhibition of proinflammatory cytokine production.		[14]

COVID-19: Coronavirus disease 2019.